| Prev Close | 14.05 |
| Day Low/High | 14.05 / 14.25 |
| 52 Wk Low/High | 10.75 / 19.85 |
| Avg Volume | 216.40K |
| Exchange | NASDAQ |
| Shares Outstanding | 42.20M |
| Market Cap | 592.95M |
| EPS | 0.80 |
| P/E Ratio | 28.10 |
| Div & Yield | 0.50 (3.60%) |
Looking at the universe of stocks we cover at Dividend Channel, on 8/3/17, Meridian Bioscience Inc. will trade ex-dividend, for its quarterly dividend of $0.125, payable on 8/17/17.
The DividendRank formula at Dividend Channel ranks a coverage universe of thousands of dividend stocks, according to a proprietary formula designed to identify those stocks that combine two important characteristics — strong fundamentals and a valuation that looks inexpensive. Meridian Bioscience Inc.
The Klein Law Firm announces the commencement of an investigation of Meridian Bioscience, Inc.
The Law Offices of Vincent Wong announce the commencement of an investigation concerning whether Meridian Bioscience, Inc.
In trading on Monday, shares of Meridian Bioscience Inc. crossed above their 200 day moving average of $15.66, changing hands as high as $15.70 per share.
The most recent short interest data was recently released for the 05/15/2017 settlement date, and Meridian Bioscience Inc. is one of the most shorted stocks of the Russell 3000, based on 9.88 "days to cover" versus the median component at 4.71.
The Law Offices of Vincent Wong announce the commencement of an investigation concerning whether Meridian Bioscience, Inc.
Glancy Prongay & Murray LLP ("GPM") announces an investigation on behalf of Meridian Bioscience, Inc.
Levi & Korsinsky announces it has commenced an investigation of Meridian Bioscience, Inc.
Kickoff panel highlights common risks and what obstetricians can do to help protect their patients
In this series, we look through the most recent Dividend Channel ''DividendRank'' report, and then we cherry pick only those companies that have experienced insider buying within the past six months. The officers and directors of a company tend to have a unique insider's view of the business, and presumably the only reason an insider would choose to take their hard-earned cash and use it to buy stock in the open market, is that they expect to make money — maybe they find the stock very undervalued, or maybe they see exciting progress within the company, or maybe both.
Field laboratory-deployable molecular test up to 80,000 times more sensitive than current options
